Evidence map›Paper›PMID 39017858›Full record

Observational studyInternational journal of hematology2024

Survival impact of response within the first year in a multicenter prospective observational study of chronic GVHD in a Japanese cohort.

Chikako Ohwada, Emiko Sakaida, Yusuke Takeda, Noriko Doki, Aiko Igarashi, Makoto Onizuka, Masako Toyosaki, Masatsugu Tanaka, Takayoshi Tachibana, Keisuke Kataoka and 14 more

Abstract readMulticenter StudyObservational Study
PubMed Publisher
In one paragraph

Observational study in International journal of hematology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Chikako OhwadaDepartment of Hematology, International University of Health and Welfare, Narita City, Chiba, 286-8520, Japan. cohwada@iuhw.ac.jp.ORCID http://orcid.org/0000-0001-9648-940X
Emiko SakaidaDepartment of Hematology, Chiba University Hospital, Chiba, Japan.
Yusuke TakedaDepartment of Hematology, Chiba University Hospital, Chiba, Japan.
Noriko DokiHematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
Aiko IgarashiHematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
Makoto OnizukaDepartment of Hematology and Oncology, Tokai University School of Medicine, Kanagawa, Japan.
Masako ToyosakiDepartment of Hematology and Oncology, Tokai University School of Medicine, Kanagawa, Japan.
Masatsugu TanakaDepartment of Hematology and Oncology, Kanagawa Cancer Center, Kanagawa, Japan.
Takayoshi TachibanaDepartment of Hematology and Oncology, Kanagawa Cancer Center, Kanagawa, Japan.
Keisuke KataokaDivision of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
Jun KatoDivision of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
Shin FujisawaDepartment of Hematology, Yokohama City University Medical Center, Kanagawa, Japan.
Seiko KatoDepartment of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Hideki NakasoneDivision of Hematology, Saitama Medical Center, Jichi Medical University, Saitama, Japan.
Ken NaganumaDepartment of Hematology, Saitama Medical Center, Saitama Medical University, Saitama, Japan.
Takayuki SaitohDepartment of Hematology, Gunma University Graduate School of Medicine, Gunma, Japan.
Katsuhiro ShonoDepartment of Hematology, Chiba Aoba Municipal Hospital, Chiba, Japan.
Maki HagiharaDepartment of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Kanagawa, Japan.
Takeshi SaitoDivision of Clinical Oncology and Hematology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
Kensuke UsukiDepartment of Hematology, NTT Medical Center, Tokyo, Japan.
Takehiko MoriDepartment of Hematology, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.
Chiaki NakasekoDepartment of Hematology, International University of Health and Welfare, Narita City, Chiba, 286-8520, Japan.
Shinichiro OkamotoDivision of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
Yoshinobu KandaDivision of Hematology, Jichi Medical University, Tochigi, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A prospective multicenter observational study of organ response was conducted in patients with chronic GVHD diagnosed by the NIH criteria. When response was assessed at 12 months (12 M) in 118 patients, 74.6% were classified as responders and 25.4% as non-responders. The skin and oral cavity were the most frequent organs used as the basis for determining overall response. The lungs, liver, and eyes were also used in 20% of patients. Non-response decisions at 12 M were most frequent in the lungs. A significantly higher percentage of responders than non-responders completed systemic treatment (24.3% vs. 3.3%, P = 0.02). Global scoring showed significant changes, with improvement in responders and worsening in non-responders throughout the observation period. Two-year transplant-related mortality, using the 12 M assessment as the landmark, was significantly worse in non-responders (28.5% vs. 2,7%, P = 0.0001), while the 2-year recurrence rate was equivalent (5.4% vs. 4.8%, P = 0.78). Consequently, the 2-year overall survival rate from the 12 M assessment was significantly better in responders than non-responders (95% vs. 65.3%, P = 0.0001). Our data suggests that patients who do not achieve a response within the first year should be candidates for clinical studies on chronic GVHD.

Indexed as

Graft vs Host DiseaseAdolescentAdultAgedChronic DiseaseEast Asian PeopleFemaleHematopoietic Stem Cell TransplantationHumansJapanMaleMiddle AgedProspective StudiesSurvival RateTime FactorsTreatment OutcomeChronic graft-versus-host-diseaseMulticenter Japanese cohortNIH consensus criteriaOrgan responseSystemic immunosuppressive therapy

Identifiers

PMID39017858

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.